TX-SNOW-SOFTWARE
16.11.2023 15:01:58 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today previewed Snow Copilot, the first-in-a-series of Artificial Intelligence (AI) capabilities designed to solve large challenges in IT Asset Management (ITAM) and FinOps. Developed in its innovation incubator Snow Labs, Snow Copilot is an AI assistant that empowers users to ask conversational questions and receive natural language responses. At release, Snow Copilot is available for Software Asset Management (SAM) computer data in Snow Atlas with more use cases being explored over time.
Snow Labs is a multiprong innovation initiative to help organizations make better decisions and deliver positive business outcomes with Technology Intelligence, or the ability to understand and manage all technology data, via Snow Atlas. The current project focuses on using artificial intelligence to advance data insights and further explore ways to tackle multifaceted ITAM and FinOps challenges, the first offering powered by Snow AI.
“We created Snow Labs as a space for rapid experimentation and prototyping, allowing us to test emerging technologies that sat outside of our standard product roadmap,” said Steve Tait, Chief Technology Officer and EVP, Research and Development at Snow. “Artificial intelligence is a great example of a rapidly evolving, emerging technology that could allow Snow Labs to address a myriad of challenges our customers face when making sense of their technology asset data. We believe that AI will fundamentally transform the way our customers and partners interact with their data. This is just one of many ways we are working to bring our vision around Technology Intelligence to life through innovation.”
Enhancing the Value of Data with Snow
IT manages vast amounts of data but struggles to turn that data into actionable intelligence for business impact. According to a recent Snow report, 91% of IT leaders said they need to invest in tools to extract more value out of their data. This is a contributing factor in the growing visibility gap between IT and the business units they support. IT struggles to know what software and cloud services are running both within IT and across the enterprise leading to technology overspend, higher security and compliance risk, reduced ITSM data quality, and slower decision-making. Generative AI provides new toolsets for Snow to tackle the visibility gap when it comes to understanding and acting on large technology asset data sets for ITAM, SaaS management, and FinOps.
Snow Copilot, one of the first AI assistants developed to solve advanced challenges for ITAM and FinOps, leverages the Microsoft Azure OpenAI Service. It allows customers to input questions and receive insights on their computer data, such as “How many computers have been installed in the last 90 days?,” as well as explore “what if” scenarios all directly within Snow Atlas. Snow Copilot reduces the need to export data into PowerBI or Excel to get insights into advanced questions on forecasting, asset allocation, and trend identification of SAM computer data. All data remains secure in the customer environment ensuring data privacy and integrity.
Additional AI-enabled features within the Snow AI umbrella are under exploration for 2024, including:
- Machine Learning Entitlement Ingestion: Eliminate manual, costly entitlement uploads with automated invoice processing powered by machine learning.
- Enhanced Data Intelligence Service (DIS) dataset with OpenAI: Receive more context about the SaaS applications running in your organization with enhanced descriptions including richer details on categories, function, etc. from the Snow DIS normalization and augmentation service.
- Fine-tuning Large Language Models (LLM) on Snow proprietary data: Make more informed and complex decisions on technology assets with personalized licensing recommendations.
These new AI capabilities will be available on Snow Atlas, the company’s Technology Intelligence platform. The platform, released in 2021, provides a more flexible and scalable foundation for continuous innovation. Snow Atlas allows organizations to bring together their ITAM, SaaS management, cloud cost and FinOps functions, providing a unified view and actionable intelligence to manage the entire IT landscape.
“The pace at which we can innovate on Snow Atlas, both in our standard product development cycles and through Snow Labs, is remarkable with more than one production release every day for the last three quarters,” said Tait. “We are entering a new era which will redefine how we work with technology, and we want to ensure organizations feel confident and prepared to embrace this monumental shift.”
Snow Copilot and other AI innovations will be available for current Snow Atlas customers who apply for the beta program. To learn more about Snow Labs and its innovation agenda, read CTO Steve Tait’s latest blog or to discover more on Snow Atlas, visit: https://www.snowsoftware.com/products/snow-atlas/.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116093425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
